Innoviva, Inc. (INVA)
19.00
-0.10
(-0.52%)
USD |
NASDAQ |
Nov 09, 16:00
19.00
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.359B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -8.92% |
| Valuation | |
| PE Ratio | 9.509 |
| PE Ratio (Forward) | |
| PS Ratio | 3.316 |
| Price to Book Value | 1.195 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.2372 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 47.01% |
Profile
| Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA. |
| URL | http://www.inva.com |
| Investor Relations URL | https://investor.inva.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | Feb. 24, 2027 (est.) |
| Last Earnings Release | Nov. 04, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 08, 2015 |
Profile
| Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA. |
| URL | http://www.inva.com |
| Investor Relations URL | https://investor.inva.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | Feb. 24, 2027 (est.) |
| Last Earnings Release | Nov. 04, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 08, 2015 |